DRISCOLL JOSEPH 4
4 · Akoya Biosciences, Inc. · Filed Dec 16, 2022
Insider Transaction Report
Form 4
DRISCOLL JOSEPH
Chief Financial Officer
Transactions
- Sale
Common Stock
2022-12-14$12.67/sh−10,039$127,187→ 12,500 total - Exercise/Conversion
Employee Stock Option (Right to Buy
2022-12-14−14,574→ 108,712 totalExercise: $0.44Exp: 2029-05-02→ Common Stock (14,574 underlying) - Exercise/Conversion
Common Stock
2022-12-14$0.44/sh+14,574$6,413→ 27,074 total - Sale
Common Stock
2022-12-14$12.46/sh−14,574$181,519→ 12,500 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2022-12-14−10,039→ 123,466 totalExercise: $0.44Exp: 2029-05-02→ Common Stock (10,039 underlying) - Exercise/Conversion
Common Stock
2022-12-14$0.44/sh+10,039$4,417→ 22,539 total
Footnotes (3)
- [F1]Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.60 - $12.80. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein.
- [F2]Column 4 reflects a weighted average price. Shares sold in multiple transactions at prices ranging from $12.40 - $12.615. Reporting person undertakes to provide issuer, securityholder of issuer or SEC staff, upon request, information regarding number of shares sold at each separate price within ranges set forth herein.
- [F3]Such performance-based option shares were issued in 2019. In 2020, the options vested as performance conditions were determined to have been achieved.